High GRP78 levels in Covid-19 infection: A case-control study

Area of Science:

• * Virology and Immunology
• * Biochemistry and Molecular Biology

Background:

• * The COVID-19 pandemic, caused by SARS-CoV-2, has had a profound global impact.
• * Glucose-regulated protein 78 (GRP78) is implicated in the entry mechanisms of various viruses.
• * Understanding GRP78's role in COVID-19 pathogenesis is crucial for developing targeted therapies.

Purpose of the Study:

• * To investigate and compare serum GRP78 protein levels across different patient groups: COVID-19 positive pneumonia, COVID-19 positive CT-negative infection, COVID-19 negative pneumonia, and healthy controls.
• * To elucidate the relationship between GRP78 expression and SARS-CoV-2 infection status.

Main Methods:

• * A case-control study involving 42 COVID-19 negative pneumonia patients, 72 COVID-19 positive patients (30 pneumonia, 42 CT-negative), and 30 healthy controls.
• * Serum GRP78 levels were quantified using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
• * Clinical and radiological evaluations were performed for patient cohort selection.

Main Results:

• * Significantly higher serum GRP78 levels were observed in the COVID-19 infection group compared to both COVID-19 negative pneumonia and control groups (p=0.031 and p=0.0001, respectively).
• * No significant difference in GRP78 levels was found among COVID-19 negative pneumonia, COVID-19 positive pneumonia, and CT-negative COVID-19 infection groups (p=0.09).
• * GRP78 levels were also significantly elevated in the COVID-19 negative pneumonia group compared to the control group (p=0.0001).

Conclusions:

• * Serum GRP78 levels are significantly increased during active COVID-19 infection.
• * The findings support a potential role for GRP78 as a biomarker or therapeutic target in COVID-19.
• * Further research into the specific association between SARS-CoV-2 and GRP78 may reveal novel treatment strategies.